Gertjan Rasschaert, Medical Doctor and Consultant specializing in Gastrointestinal Oncology and Gastroenterology at UZ Leuven, shared a post on LinkedIn:
“First patient dosed worldwide today in AZUR4 at UZ Leuven.
AZUR-4 is a phase 2, open label, randomized study of neoadjuvant dostarlimab + CAPEOX versus CAPEOX, followed by surgery, in previously untreated locally advanced pMMR/MSS colon cancer.
While the exact relevance of pCR as a surrogate endpoint remains an important question for debate, still, very curious where we will land. Time will tell.”
